Key Performance
More- Earnings Score: N/A
- Momentum Score: 76
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Aclarion, Inc. announced an agreement with the Institute of Neuro Innovation (INI) in Los Angeles to expand availability of its Nociscan platform and generate real-world evidence. The partnership will evaluate how Nociscan's chemical biomarker measurements work alongside SPECT-CT imaging to improve diagnostic precision for chronic low back pain treatment decisions.
06/03/2026, 6:00 AM • GlobeNewswire
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
Aclarion's Nociscan MRS technology was used in an NIH-funded study that won the 2026 ISSLS Best Paper Award. The research found that elevated propionic acid levels in lumbar discs can identify a subgroup of Modic type 1 patients with distinct immune activation, suggesting potential applications beyond surgical decision support for personalized spine care and immune-modulating therapies.
06/01/2026, 6:00 AM • GlobeNewswire
Aclarion, Inc. announced the appointment of Daniel Keefe as Commercial Director for the Western U.S. to expand adoption of its Nociscan platform, a cloud-based diagnostic tool for identifying sources of chronic low back pain. The appointment reflects strong triple-digit growth in utilization and the company's strategic focus on deepening market presence in the Western region. Keefe brings over 20 years of medical device sales experience from companies including Zimmer Biomet and Intuitive Surgical.
04/28/2026, 6:00 AM • GlobeNewswire
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
Aclarion announced its 2026 strategic priorities including pursuing reimbursement coverage from regional US insurance providers, an initial CLARITY trial readout expected in Q4 2026, and maintaining a strong balance sheet with cash runway into 2028. The company continues expanding adoption of its Nociscan platform for identifying chronic low back pain sources.
03/19/2026, 6:00 AM • GlobeNewswire
Aclarion, Inc. announced its participation in the 38th Annual ROTH Conference (March 22-24, 2026) where CEO Brent Ness will meet with institutional investors and analysts. The company highlighted its strong balance sheet with no debt and plans to expand adoption of Nociscan, its MR spectroscopy platform for identifying painful discs in chronic low back pain patients, in both the UK and US markets.
03/17/2026, 6:00 AM • GlobeNewswire
Aclarion CEO Brent Ness to Attend LSI USA 2026
Aclarion, Inc. announced that CEO Brent Ness will attend LSI USA 2026 (March 16-20 in Dana Point, CA) to meet with investors and industry partners regarding the company's NOCISCAN platform. NOCISCAN is a proprietary MR spectroscopy platform using AI and biomarkers to help physicians identify painful discs in chronic low back pain patients.
03/12/2026, 6:00 AM • GlobeNewswire
Aclarion Publishes 2026 Shareholder Letter from the Chairman
Aclarion, Inc. announced a strengthened financial position with cash runway extending into 2028, eliminating the need for capital raises before key clinical milestones. The company terminated its ATM and ELOC, reinforcing shareholder alignment. Aclarion expects an initial internal readout of its 300-patient CLARITY trial at the end of Q3 2026 and public disclosure of early interim results in Q4 2026.
02/05/2026, 6:00 AM • GlobeNewswire
Aclarion, Inc. announced an agreement with Source Healthcare, a Los Angeles-based orthopedic clinic, to expand availability of Nociscan and generate real-world evidence comparing the non-invasive diagnostic tool to anesthetic discography. The partnership supports Aclarion's growth strategy in the chronic low back pain market and aims to build clinical data for payer and provider adoption.
02/03/2026, 6:00 AM • GlobeNewswire
Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout
Aclarion (NASDAQ: ACON) raised $10.4 million through common stock financing at $5.18 per share, extending its cash runway into 2028 with zero debt and $21.6 million in cash. The company plans to accelerate clinical trials for its Nociscan AI platform, expand access across MRI platforms, and pursue broader reimbursement. Despite strong 2025 adoption metrics (69% YoY scan volume growth), the stock fell 5.21% to $4.27, trading at a new 52-week low.
01/13/2026, 10:51 AM • Benzinga
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
Aclarion, Inc. closed a $10.4 million common-stock financing at $5.18 per share, bringing cash reserves to $21.6 million with zero debt and extended runway into 2028. The company plans to advance its Nociscan clinical trial (CLARITY), expand MRI manufacturer access, and pursue broader payor coverage for its chronic low back pain diagnostic platform.
01/13/2026, 6:00 AM • GlobeNewswire
Aclarion Provides 2025 Update and 2026 Corporate Outlook
Aclarion, a healthcare technology company, reported 69% year-over-year growth in Nociscan scan volumes for 2025, with Q4 showing 114% growth. The company maintains a debt-free balance sheet with $12.0 million in cash, providing runway into 2027. Aclarion is advancing its CLARITY clinical trial with plans to enroll 25% of patients by Q2 2026 and expects initial interim data in Q3 2026. The company added 9 new imaging centers and 22 physician users in 2025, and published clinical evidence supporting Nociscan's cost-effectiveness.
01/08/2026, 6:00 AM • GlobeNewswire
Aclarion announced that Northwestern Medicine and Scripps Health have enrolled their first patients in the CLARITY pivotal trial, bringing the total to four sites with patient enrollments. Seven clinical sites have completed regulatory requirements and are ready to enroll. The company expects initial data readout in Q3 2026 after the first cohort completes 3-month follow-up visits. The trial aims to demonstrate that Nociscan improves surgical outcomes for chronic low back pain beyond the current 54% industry benchmark.
01/06/2026, 6:00 AM • GlobeNewswire
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
Aclarion, a healthcare technology company, was named a Rising Star in the Clinical Diagnostic Device category at the 2025 Digital Health Hub Foundation Awards. The company's Nociscan solution helps physicians identify chronic low back pain sources using MR spectroscopy and AI algorithms.
10/22/2025, 6:00 AM • GlobeNewswire
Aclarion presented at the International Society of Pain and Neuroscience Annual Meeting in London, highlighting its Nociscan technology that uses MR Spectroscopy and AI algorithms to help physicians identify the source of chronic low back pain.
10/13/2025, 6:00 AM • GlobeNewswire
Aclarion, a healthcare technology company, was selected as a finalist in the Rising Star - Clinical Diagnostic Device category for the 2025 Digital Health Hub Foundation Awards. Their Nociscan solution aims to help physicians identify the location of chronic low back pain using innovative MR spectroscopy and AI algorithms.
10/07/2025, 6:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.